Atomoxetine HCl Clinical Trials

Size	Price	Qty
10mg	USD 147

Clinical Trials

Numerous clinical trials spanning Phase 1 through Phase 4 evaluate atomoxetine across diverse indications, primarily attention-deficit/hyperactivity disorder (ADHD), alongside morbid obesity, mild cognitive impairment, fetal alcohol syndrome, and substance use disorders. Sponsored by pharmaceutical companies, academic institutions, and government agencies like the National Institute on Drug Abuse, these investigations encompass statuses ranging from recruiting and active to completed, withdrawn, and terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07724132	RECRUITING	Alzheimer's Disease (AD); Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer Disease Dementia	University College, London	2026-07-24	PHASE3
NCT04216186	RECRUITING	ADHD	Sherief Abd-Elsalam	2018-11-01	PHASE3
NCT07679282	NOT_YET_RECRUITING	Obstructive Sleep Apnea (OSA)	Sairam Parthasarathy	2026-09-01	PHASE4
NCT00262470	ACTIVE_NOT_RECRUITING	Tachycardia; Chronic Orthostatic Intolerance	Satish R. Raj	1997-04	PHASE1; PHASE2
NCT06573970	RECRUITING	Posttraumatic Stress Disorder With Attention Defic	VA Office of Research and Development	2026-04-01	PHASE4
NCT06899178	RECRUITING	Melanocortin Obesity Syndrome; MCOS	Icahn School of Medicine at Mount Sinai	2026-09-01	PHASE2
NCT07577661	NOT_YET_RECRUITING	Obstructive Sleep Apnea; Sleep-disordered Breathing	Brigham and Women's Hospital	2026-06-01	PHASE1; PHASE2
NCT07239791	RECRUITING	Role of the Noradrenergic System in the Regulation of Learning Dynamics; No Disease or Condition is Being Studied	Centre Hospitalier St Anne	2025-11-18
NCT07771595	NOT_YET_RECRUITING	Apathy	University of Oxford	2026-08	PHASE4
NCT07316296	RECRUITING	Parkinson's Disease (PD); Freezing of Gait; Freezing of Gait Symptoms in Parkinson Disease	Radboud University Medical Center	2026-01-01	PHASE3
NCT04782830	RECRUITING	Orthostatic; Hypotension, Neurogenic; Autonomic Failure; Pure Autonomic Failure; Multiple System Atrophy; Orthostatic; Hypotension, Parkinsonism	Vanderbilt University Medical Center	2021-02-05
NCT05350215	RECRUITING	Obstructive Sleep Apnea	Brigham and Women's Hospital	2022-06-01	PHASE1; PHASE2
NCT07251348	ACTIVE_NOT_RECRUITING	Hematological Cancer	Necmettin Erbakan University	2026-02-01
NCT05293600	RECRUITING	Obstructive Sleep Apnea	Brigham and Women's Hospital	2023-07-01	PHASE1; PHASE2
NCT05159687	RECRUITING	Vasovagal Syncope	University of Calgary	2022-06-01	PHASE3
NCT06566820	ENROLLING_BY_INVITATION	OSA	Apnimed	2024-07-03	PHASE3
NCT05933603	ACTIVE_NOT_RECRUITING	Obstructive Sleep Apnea; Down Syndrome	University of Arizona	2023-09-29	PHASE2
NCT02879136	COMPLETED	Parkinson's Disease, Idiopathic	Hubert Fernandez	2017-01-03	EARLY_PHASE1
NCT06295562	COMPLETED	Obstructive Sleep Apnea of Adult	China Medical University Hospital	2024-11-05	PHASE4
NCT06542887	UNKNOWN	ADHD	Ain Shams University	2024-10-01	PHASE2
NCT03781765	UNKNOWN	ADHD; Attention Deficit Hyperactivity Disorder	Icahn School of Medicine at Mount Sinai	2019-06-04	PHASE4
NCT04085172	COMPLETED	Attention Deficit Hyperactivity Disorder	Shire	2019-09-18	PHASE4
NCT06841666	NOT_YET_RECRUITING	ADHD; Primary Nocturnal Enuresis	Tanta University	2025-02-28	EARLY_PHASE1
NCT05944965	COMPLETED	OSA	Brigham and Women's Hospital	2023-12-01	PHASE1; PHASE2
NCT05811247	COMPLETED	OSA	Apnimed	2023-08-28	PHASE3
NCT05813275	COMPLETED	OSA	Apnimed	2023-09-16	PHASE3
NCT06400615	COMPLETED	OSA	Apnimed	2024-05-20	PHASE2
NCT05550246	UNKNOWN	Obstructive Sleep Apnea	Brigham and Women's Hospital	2022-05-05	PHASE1; PHASE2
NCT05278104	COMPLETED	Attention Deficit Hyperactivity Disorder	Boehringer Ingelheim	2023-09-14
NCT05351944	COMPLETED	Impulsive Aggression; ADHD; Executive Dysfunction	Alexandria University	2023-05-07
NCT04354103	TERMINATED	Tourette Syndrome	Poitiers University Hospital	2022-05-31	PHASE2
NCT03919955	COMPLETED	Sleep Apnea	Brigham and Women's Hospital	2019-09-03	PHASE2
NCT04565288	COMPLETED	Alcohol Use Disorder	Brown University	2021-05-06	PHASE2
NCT04905979	COMPLETED	Obstructive Sleep Apnea; Hypertension	Apnimed	2021-07-31	PHASE2
NCT04115878	COMPLETED	Obstructive Sleep Apnea; Down Syndrome	University of Arizona	2020-10-21	PHASE2
NCT05071612	COMPLETED	OSA - Obstructive Sleep Apnea	Apnimed	2021-11-29	PHASE2
NCT05101122	COMPLETED	Obstructive Sleep Apnea	Apnimed	2021-10-19	PHASE1; PHASE2
NCT03808740	TERMINATED	Orthostatic Intolerance	Vanderbilt University Medical Center	2018-07-01	PHASE1
NCT04580394	COMPLETED	Obstructive Sleep Apnea	Apnimed	2020-10-27	PHASE2
NCT02784535	COMPLETED	Neurogenic Orthostatic Hypotension	Vanderbilt University Medical Center	2016-08-29	PHASE2
NCT03936491	COMPLETED	Attention Deficit Hyperactivity Disorder	National Taiwan University Hospital	2019-08-01
NCT04445688	COMPLETED	Obstructive Sleep Apnea	Apnimed	2020-07-15	PHASE2
NCT03350659	COMPLETED	Neurogenic Orthostatic Hypotension	Seoul National University Hospital	2018-01-01	PHASE4
NCT03324581	COMPLETED	Adult Attention Deficit Hyperactivity Disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	2017-11-09	PHASE2
NCT00780650	COMPLETED	Type 1 Diabetes	University of Maryland, Baltimore	2009-05	EARLY_PHASE1
NCT03091400	COMPLETED	Memory Disorders; Multiple Sclerosis	Icahn School of Medicine at Mount Sinai	2017-03-16	PHASE2
NCT01678209	COMPLETED	Attention Deficit Hyperactivity Disorder; ADHD	Icahn School of Medicine at Mount Sinai	2012-10	PHASE4
NCT02500732	COMPLETED	Vasovagal Syncope	University of Calgary	2015-07	PHASE2
NCT03661788	COMPLETED	ADHD	RWTH Aachen University	2016-05	PHASE4
NCT03154359	Completed	ADHD	Children''s Mercy Hospital Kansas City\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2017-12-12	--
NCT02908529	COMPLETED	Obstructive Sleep Apnea (OSA)	Brigham and Women's Hospital	2016-09	PHASE1; PHASE2
NCT01522404	COMPLETED	Mild Cognitive Impairment	Emory University	2012-03	PHASE2
NCT02287038	COMPLETED	Post Traumatic Stress Disorder; Attention Deficit Hyperactivity Disorder	VA Office of Research and Development	2014-10-15	PHASE4
NCT02046551	WITHDRAWN	Nicotine Dependence	Yale University	2014-04	PHASE1; PHASE2
NCT00223691	COMPLETED	Autonomic Failure; Orthostatic Hypotension	Vanderbilt University	2002-03	PHASE1
NCT03460210	Recruiting	Obesity Morbid	Norwegian University of Science and Technology\|St. Olavs Hospital\|Volvat Medisinsk Senter Stokkan\|Namsos Hospital\|Alesund Hospital	2016-11-02	--
NCT02623114	UNKNOWN	Attention-deficit/Hyperactivity Disorder	Seoul National University Childrens Hospital	2012-05	PHASE4
NCT00716274	COMPLETED	Attention Deficit Hyperactivity Disorder; Dyslexia	Eli Lilly and Company	2008-09	PHASE4
NCT01330693	UNKNOWN	Attention Deficit Disorder With Hyperactivity	University of Cincinnati	2009-09	PHASE3
NCT00498173	COMPLETED	Autism	Massachusetts General Hospital	2007-07	PHASE3
NCT02482649	UNKNOWN	Attention Deficit Hyperactivity Disorder	Samsung Medical Center	2013-01
NCT01557569	COMPLETED	Methamphetamine Dependence	University of Arkansas	2012-04	PHASE1; PHASE2
NCT01133847	COMPLETED	Attention Deficit Hyperactivity Disorder; Reading Disabilities	The University of Texas Health Science Center, Houston	2010-11	PHASE4
NCT00418262	COMPLETED	Fetal Alcohol Syndrome; Attention Deficit Hyperactivity Disorder (ADHD)	University of Oklahoma	2005-08	PHASE3
NCT00417794	COMPLETED	Fetal Alcohol Syndrome; Attention Deficit Disorder With Hyperactivity (ADHD); Attention Deficit Disorder (ADD)	University of Oklahoma	2005-08	PHASE1
NCT02352051	COMPLETED	Executive Dysfunction	TC Erciyes University	2014-02	PHASE4
NCT01738191	COMPLETED	Parkinson's Disease; Cognitive Impairment	Medical University of South Carolina	2012-11	PHASE2
NCT01863251	COMPLETED	Opiate Dependence; Stimulant Dependence	Yale University	2013-05	PHASE2
NCT00844753	COMPLETED	Autism; Pervasive Development Disorder; Asperger's Disorder; Attention Deficit Hyperactivity Disorder	University of Rochester	2008-10	PHASE4
NCT01802515	TERMINATED	Cocaine Dependence; Opiate Dependence	Yale University	2012-12
NCT03651856	COMPLETED	Parkinson's Disease; Freezing of Gait	Medical University of South Carolina	2013-01	PHASE3
NCT01498549	COMPLETED	Addiction	Yale University	2011-12
NCT01244490	COMPLETED	Attention Deficit Hyperactivity Disorder	Shire	2011-01-17	PHASE3
NCT02788357	COMPLETED	Atomoxetine Hydrochloride; Placebos	Lumy Sawaki	2006-11	PHASE2
NCT01794975	COMPLETED	Changes in Striatal [11C]ORM-13070 Binding.	University of Turku	2012-08	PHASE1
NCT01741376	WITHDRAWN	Cocaine Dependence; Nicotine Dependence	University of Minnesota	2012-11
NCT02014064	COMPLETED	Continuous Methamphetamine Dependence; Methamphetamine Dependence in Remission	University of California, Los Angeles	2009-08	PHASE1
NCT01106430	COMPLETED	Attention-Deficit/Hyperactivity Disorder	Shire	2010-06-28	PHASE3
NCT01522404	Completed	Mild Cognitive Impairment	Emory University\|National Institute on Aging (NIA)	2012-03	Phase 2
NCT00702364	COMPLETED	Traumatic Brain INjury	Craig Hospital	2008-01
NCT01343628	TERMINATED	Alcohol-induced Cue-craving; Alcohol Sensitivity	University of Virginia	2008-01	PHASE1
NCT01435213	COMPLETED	Healthy	University of Turku	2011-09	PHASE1
NCT00969618	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2009-11	PHASE3
NCT00697138	COMPLETED	Cocaine Dependence	University of Kentucky	2006-06	PHASE1
NCT01339286	UNKNOWN	Attention Deficit Hyperactivity Disorder	Peking University	2011-03	PHASE4
NCT00548327	TERMINATED	Schizophrenia; Memory Disorders; Cognition Disorders	National Institute of Mental Health (NIMH)	2007-10	PHASE2
NCT00700427	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2008-06	PHASE3
NCT00617201	COMPLETED	Substance Abuse	Sharon Walsh	2007-07	PHASE2
NCT00183391	COMPLETED	Attention Deficit Disorder With Hyperactivity	Icahn School of Medicine at Mount Sinai	2005-07	PHASE4
NCT01127646	TERMINATED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2010-06	PHASE4
NCT01709695	Completed	ADHD\|Attention Deficit Hyperactivity Disorder	Icahn School of Medicine at Mount Sinai	2011-03	Phase 4
NCT00628394	COMPLETED	Cognition in Schizophrenia	University of Texas Southwestern Medical Center	2003-09	PHASE4
NCT00962104	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2009-08	PHASE3
NCT01065259	COMPLETED	Attention Deficit Hyperactivity Disorder	Peking University	2008-04	PHASE4
NCT01019707	TERMINATED	Methamphetamine Abuse; Methamphetamine Dependence	University of California, Los Angeles	2009-10	PHASE1
NCT00607919	COMPLETED	Attention Deficit Hyperactivity Disorder; Dyslexia	Eli Lilly and Company	2008-03	PHASE4
NCT01177943	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2010-08	PHASE1
NCT00760747	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2008-09	PHASE4
NCT00880217	COMPLETED	Attention Deficit Hyperactivity Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-05	PHASE2
NCT00938743	COMPLETED	Attention Deficit Hyperactivity Disorder	Central Institute of Mental Health, Mannheim	2008-01	PHASE4
NCT00856063	COMPLETED	Attention Deficit Hyperactivity Disorder	University of Arizona	2009-03	PHASE4
NCT00190684	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2000-08	PHASE3
NCT00191386	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2005-05	PHASE3
NCT00190775	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-09	PHASE4
NCT00687609	TERMINATED	Attention Deficit Hyperactivity Disorder; Cannabis Abuse	Eli Lilly and Company	2008-09	PHASE4
NCT00546910	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2007-10	PHASE4
NCT00447278	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2007-03	PHASE3
NCT00510276	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2007-08	PHASE4
NCT00406354	COMPLETED	Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder	Eli Lilly and Company	2006-11	PHASE4
NCT00566371	COMPLETED	Attention Deficit Hyperactivity Disorder; Insomnia	Rhode Island Hospital	2005-06	PHASE4
NCT00304161	COMPLETED	Depressive Disorder; Parkinson Disease	University of Pennsylvania	2004-07	PHASE4
NCT00471354	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2007-04	PHASE4
NCT00568685	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2007-11	PHASE3
NCT00320528	COMPLETED	Attention Deficit Disorder With Hyperactivity	Eli Lilly and Company	2006-04	PHASE3
NCT00636818	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2008-03	PHASE2
NCT00254462	COMPLETED	Attention Deficit Disorder With Hyperactivity	University of Nebraska	2005-10-01	PHASE4
NCT00181766	COMPLETED	ADHD NOS	Massachusetts General Hospital	2003-12	PHASE4
NCT00260533	COMPLETED	Generalized Social Phobia	University of California, San Diego	2005-11	PHASE2; PHASE3
NCT00286949	COMPLETED	Parkinson's Disease	Johns Hopkins University	2005-01-06
NCT00360269	COMPLETED	Marijuana Abuse; Attention Deficit Disorder With Hyperactivity	Medical University of South Carolina	2005-11	PHASE2
NCT00380692	COMPLETED	Autistic Disorder; Attention Deficit Disorder With Hyperactivity	Eli Lilly and Company	2006-10	PHASE4
NCT00918567	COMPLETED	Attention Deficit Hyperactivity Disorder	State University of New York at Buffalo	2007-01	PHASE4
NCT00530335	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2007-09	PHASE2
NCT00611533	COMPLETED	Menopause; Cognitive Disturbances	University of Pennsylvania	2004-05
NCT00953862	COMPLETED	Attention Deficit Hyperactivity Disorder	NYU Langone Health	2005-07
NCT00528697	COMPLETED	Attention-Deficit/Hyperactivity Disorder	AbbVie (prior sponsor, Abbott)	2007-09	PHASE2
NCT00517647	COMPLETED	Attention Deficit Hyperactivity Disorder	University of Arizona	2004-04	PHASE4
NCT00176436	COMPLETED	Schizophrenia	University of Maryland, Baltimore	2004-02	PHASE4
NCT00191945	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2005-05	PHASE3
NCT00368849	COMPLETED	Huntington Disease; Chorea	University of Iowa	2005-11	PHASE2
NCT00399763	COMPLETED	Attention Deficit Hyperactivity Disorder; Substance Abuse	Denver Health and Hospital Authority	2005-09
NCT00585910	COMPLETED	ADHD; Attention Deficit Hyperactivity Disorder	Massachusetts General Hospital	2004-01	PHASE4
NCT00191906	COMPLETED	Attention Deficit Hyperactivity Disorder; Reading Disorder	Eli Lilly and Company	2005-04	PHASE4
NCT01408589	TERMINATED	Alcohol Craving; Mood Changes	University of Colorado, Boulder	2005-06	PHASE1
NCT00299234	TERMINATED	Attention Deficit Hyperactivity Disorder	Monarch Medical Research	2006-06	PHASE4
NCT00181948	COMPLETED	ADHD	Massachusetts General Hospital	2004-09	PHASE4
NCT00429091	COMPLETED	Attention-Deficit/Hyperactivity Disorder; ADHD	Abbott	2007-01	PHASE2
NCT00607568	COMPLETED	Physiological Stress	Yale University	2006-06	PHASE1; PHASE2
NCT00611936	COMPLETED	Stress	Yale University	2006-06	PHASE1; PHASE2
NCT00488163	COMPLETED	Schizophrenia	Research Foundation for Mental Hygiene, Inc.	2005-01	PHASE4
NCT00327834	COMPLETED	Binge-eating Disorder	Lindner Center of HOPE	2006-05	PHASE4
NCT00218543	COMPLETED	Attention Deficit Disorder With Hyperactivity; Cocaine-Related Disorders	New York State Psychiatric Institute	2004-06	PHASE2
NCT00142961	COMPLETED	Attention Deficit Disorder With Hyperactivity; Marijuana Abuse	New York State Psychiatric Institute	2005-10	PHASE2
NCT00161031	COMPLETED	Schizophrenia	University of Maryland, Baltimore	2004-04
NCT00216281	TERMINATED	Schizophrenia	Indiana University	2005-09	PHASE3
NCT00265265	COMPLETED	Cocaine-Related Disorders	National Institute on Drug Abuse (NIDA)	2005-08	PHASE1
NCT00192023	COMPLETED	Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder	Eli Lilly and Company	2004-10	PHASE3
NCT00218322	COMPLETED	Attention Deficit Disorder With Hyperactivity; Substance-Related Disorders	Massachusetts General Hospital	2004-09	PHASE4
NCT00167297	COMPLETED	Cannabis Dependence	National Institute on Drug Abuse (NIDA)	2004-11	PHASE2
NCT00191698	COMPLETED	Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder	Eli Lilly and Company	2003-12	PHASE3
NCT00557960	COMPLETED	Attention Deficit Disorder With Hyperactivity	Shire	2004-02-25	PHASE3
NCT00506727	COMPLETED	ADHD	Shire	2003-08-05	PHASE4
NCT00191295	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2005-02	PHASE2; PHASE3
NCT00216918	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2005-09	PHASE4
NCT00191737	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-10	PHASE3
NCT01207622	WITHDRAWN	Attention Deficit Hyperactivity Disorder; Substance Use Disorder	Massachusetts General Hospital		PHASE4
NCT00191880	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-05	PHASE3
NCT00386581	COMPLETED	Attention Deficit Disorder With Hyperactivity	Eli Lilly and Company	2004-07	PHASE3
NCT00485849	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-02	PHASE4
NCT00255138	WITHDRAWN	Cancer; Cognitive Late Effects	Temple University	2005-11	PHASE3
NCT00485875	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-06	PHASE4
NCT00190957	COMPLETED	ADHD; Comorbid Alcohol Abuse	Eli Lilly and Company	2004-08	PHASE4
NCT00190736	COMPLETED	ADHD	Eli Lilly and Company	2004-09	PHASE4
NCT00420498	COMPLETED	Schizophrenia; Cognition; Smoking	Yale University	2005-08	PHASE2
NCT00191633	COMPLETED	Attention-Deficit/Hyperactivity Disorder	Eli Lilly and Company	2005-04	PHASE4
NCT00181740	COMPLETED	ADHD NOS	Massachusetts General Hospital	2003-12	PHASE4
NCT00485862	COMPLETED	Depressive Symptoms	Eli Lilly and Company	2003-06	PHASE4
NCT00485628	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2003-04	PHASE2
NCT00190879	COMPLETED	Attention Deficit Hyperactivity Disorder; Comorbid Social Anxiety Disorder	Eli Lilly and Company	2005-06	PHASE4
NCT00485459	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-02	PHASE3
NCT00191009	COMPLETED	Alzheimer Disease	Eli Lilly and Company	2003-10	PHASE2; PHASE3
NCT00866996	COMPLETED	Attention Deficit Hyperactivity Disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.		PHASE4
NCT00486083	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2003-12	PHASE3
NCT00485407	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2003-07	PHASE3
NCT00222794	COMPLETED	Schizophrenia; Schizoaffective Disorder	University of Pittsburgh	2003-11	PHASE4
NCT00089869	COMPLETED	Schizophrenia	Eli Lilly and Company		PHASE1; PHASE2
NCT00252278	UNKNOWN	Attention-Deficit/Hyperactivity Disorder (ADHD); Insomnia	Rhode Island Hospital	2005-11	PHASE4
NCT00191048	COMPLETED	Attention-Deficit/Hyperactivity Disorder; Comorbid Dyslexia	Eli Lilly and Company	2003-10	PHASE4
NCT00486122	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2003-09	PHASE4
NCT00191542	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2005-03	PHASE3
NCT00190931	COMPLETED	Attention Deficit Disorder With Hyperactivity	Eli Lilly and Company	2003-11	PHASE4
NCT00191659	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-06	PHASE3
NCT00191516	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-10	PHASE3
NCT00485550	COMPLETED	Attention Deficit Hyperactivity Disorder	Eli Lilly and Company	2004-01	PHASE3
NCT00191035	COMPLETED	Attention-Deficit/Hyperactivity Disorder	Eli Lilly and Company	2004-03	PHASE4
NCT00562055	WITHDRAWN	Attention Deficit Hyperactivity Disorder	Pfizer	2007-11	PHASE2
NCT00029614	COMPLETED	Substance Use Disorders; Attention Deficit Hyperactivity Disorder	University of Pittsburgh	2006-05	PHASE2
NCT00174226	COMPLETED	Attention Deficit Disorder With Hyperactivity	Pfizer	2004-11	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-23)

Check the Atomoxetine HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Atomoxetine acts as a potent and selective inhibitor of the presynaptic norepinephrine transporter with a Ki of 5 nM, thereby blocking the reuptake of extracellular norepinephrine into presynaptic neurons and increasing synaptic neurotransmitter availability. This enhancement of central noradrenergic signaling improves executive function and attentional control, providing the mechanistic rationale for its clinical application in attention-deficit/hyperactivity disorder and mild cognitive impairment.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).